CLI and PAD Treatment Market Size, Share, Growth, and Industry Analysis, By Type ( CLI Treatment,PAD Treatment ), By Application ( Hospitals,Ambulatory Surgical Centers ), Regional Insights and Forecast to 2035

CLI and PAD Treatment Market Overview

Global CLI and PAD Treatment market size is anticipated to be worth USD 5912.17 million in 2026, projected to reach USD 10531.28 million by 2035 at a 6.7% CAGR.

The CLI and PAD Treatment Market is driven by the increasing prevalence of peripheral artery disease affecting over 230 million people globally, with nearly 10% of adults above 55 years diagnosed. Critical limb ischemia (CLI), the advanced stage of PAD, accounts for approximately 1% to 2% of all PAD cases, yet contributes to nearly 25% of amputations annually. Endovascular procedures represent over 60% of interventions, while surgical bypass accounts for around 25%. Drug-coated balloons and stents are used in nearly 45% of procedures. The CLI and PAD Treatment Market Report highlights that hospital-based treatments account for over 70% of procedures worldwide.

In the United States, approximately 8.5 million individuals are affected by PAD, with nearly 12% prevalence among people aged over 60 years. CLI impacts nearly 1.5 million patients annually, leading to over 150,000 amputations per year. Around 65% of PAD patients remain undiagnosed, increasing disease burden. Endovascular therapy adoption exceeds 70% in U.S. hospitals, while ambulatory surgical centers perform nearly 30% of procedures. Medicare covers nearly 80% of PAD-related procedures for patients above 65 years. The CLI and PAD Treatment Market Analysis shows that smoking contributes to over 40% of PAD cases in the U.S.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 65% of PAD cases are linked to lifestyle factors, while 72% of patients above 60 years exhibit arterial blockages, and nearly 58% of procedures involve minimally invasive techniques, indicating rising demand driven by aging populations and high-risk comorbidities.
• Major Market Restraint: Approximately 48% of patients face delayed diagnosis, while 35% of treatment centers lack advanced devices, and nearly 28% of procedures experience reimbursement limitations, restricting access and slowing procedural adoption across emerging economies.
• Emerging Trends: Drug-coated devices account for nearly 45% usage, while 52% of clinicians prefer endovascular-first strategies, and 38% of patients undergo outpatient procedures, reflecting a shift toward minimally invasive and cost-efficient treatment modalities globally.
• Regional Leadership: North America holds approximately 38% market share, Europe contributes around 27%, Asia-Pacific accounts for nearly 24%, and Middle East & Africa represent about 11%, driven by healthcare infrastructure and disease prevalence differences.
• Competitive Landscape: Top 5 companies control nearly 62% of total market share, while 30% is fragmented among regional players, and 18% is occupied by emerging device manufacturers focusing on innovative catheter-based solutions and stent technologies.
• Market Segmentation: PAD treatment accounts for approximately 68% of total procedures, while CLI treatment represents around 32%, with hospitals contributing 72% of procedures and ambulatory centers handling nearly 28% globally.
• Recent Development: Nearly 41% of new product launches involve drug-eluting technologies, while 36% focus on imaging integration, and 29% of companies increased R&D spending by over 15% between 2023 and 2025.

CLI and PAD Treatment Market Latest Trends

The CLI and PAD Treatment Market Trends indicate a strong shift toward minimally invasive procedures, with over 60% of interventions now performed using endovascular techniques compared to 40% a decade ago. Drug-coated balloons have gained traction, accounting for nearly 45% of total angioplasty procedures, while atherectomy devices are used in approximately 30% of complex PAD cases. The adoption of imaging technologies such as intravascular ultrasound has increased by nearly 35% in the last 5 years, improving procedural accuracy. The CLI and PAD Treatment Market Insights highlight that outpatient procedures have increased by nearly 38%, reducing hospital stays by an average of 2 to 3 days per patient.

Additionally, over 50% of vascular specialists now prefer hybrid procedures combining surgical and endovascular approaches. The prevalence of diabetes, affecting nearly 537 million people globally, contributes to over 60% of CLI cases, increasing demand for advanced treatments. Technological advancements have resulted in nearly 25% reduction in restenosis rates with drug-eluting stents. Robotic-assisted vascular procedures are emerging, currently accounting for around 5% of interventions but expected to increase due to improved precision. The CLI and PAD Treatment Market Growth is further supported by increased screening, with ankle-brachial index testing rising by nearly 20% in primary care settings.

CLI and PAD Treatment Market Dynamics

The CLI and PAD Treatment Market Dynamics are shaped by increasing disease prevalence, technological advancements, and healthcare accessibility variations. Globally, over 230 million individuals are affected by PAD, while nearly 1% to 2% progress to CLI, contributing to approximately 25% of limb amputations annually. Endovascular procedures account for more than 60% of treatments, reflecting a shift toward minimally invasive care. However, nearly 50% of patients remain undiagnosed, delaying treatment and increasing complication risks by over 35%. Diabetes, affecting more than 10% of the global population, contributes to over 60% of CLI cases, intensifying demand for advanced interventions. Drug-coated devices are used in approximately 45% of procedures, reducing restenosis rates by nearly 20%. Despite advancements, procedural complications occur in about 15% of cases, and recurrence rates remain close to 30% within 12 months, impacting long-term outcomes and increasing treatment complexity.

DRIVER

"Rising prevalence of vascular diseases and aging population."

The CLI and PAD Treatment Market Growth is primarily driven by the increasing incidence of vascular diseases, with PAD affecting over 200 million individuals globally and CLI impacting approximately 1% to 2% of these cases. Aging populations contribute significantly, as nearly 20% of individuals above 70 years develop PAD symptoms. Diabetes prevalence, affecting over 10% of adults worldwide, increases PAD risk by nearly 4 times, while smoking contributes to over 40% of cases. Hospitals report that over 65% of vascular procedures are related to PAD complications, highlighting the growing demand for treatment solutions. Additionally, obesity rates exceeding 30% in several countries further accelerate disease progression.

RESTRAINT

"Limited awareness and delayed diagnosis."

Despite high prevalence, nearly 50% of PAD patients remain undiagnosed, delaying treatment initiation and increasing complication rates by over 35%. Screening rates remain low, with only 25% of at-risk populations undergoing diagnostic tests. In developing regions, less than 20% of healthcare facilities have access to advanced imaging technologies. Reimbursement challenges affect nearly 30% of patients, limiting access to innovative treatments. Additionally, procedural costs increase by nearly 40% in advanced cases due to complications, discouraging early intervention. Physician awareness gaps also contribute, with only 45% of primary care providers routinely screening high-risk patients.

OPPORTUNITY

"Growth in minimally invasive and outpatient procedures."

The CLI and PAD Treatment Market Opportunities are expanding with the rise of minimally invasive procedures, which now account for over 60% of interventions globally. Ambulatory surgical centers perform nearly 30% of procedures, reducing costs by approximately 25% compared to hospital settings. Drug-coated technologies reduce restenosis rates by nearly 20%, improving long-term outcomes. Emerging markets show potential, with healthcare infrastructure expanding by over 15% annually in certain regions. Telemedicine adoption has increased by nearly 40%, enabling remote diagnosis and monitoring. Furthermore, wearable diagnostic devices are used by approximately 18% of patients, improving early detection rates.

CHALLENGE

"High recurrence rates and procedural complications."

One of the major challenges in the CLI and PAD Treatment Industry Analysis is the recurrence of arterial blockages, with restenosis occurring in nearly 30% of cases within 12 months. Amputation rates remain high, with approximately 20% of CLI patients requiring major limb amputation within 1 year of diagnosis. Procedural complications such as bleeding and infection occur in nearly 15% of interventions. Additionally, patient compliance with post-procedure care is below 60%, increasing the risk of disease progression. Device failure rates, although reduced, still account for nearly 10% of cases, impacting treatment effectiveness and increasing healthcare burden.

CLI and PAD Treatment Market Segmentation

The CLI and PAD Treatment Market Segmentation is divided into type and application, with PAD treatment accounting for approximately 68% of total procedures and CLI treatment representing around 32%. Hospitals dominate with nearly 72% share, while ambulatory surgical centers contribute around 28%. The CLI and PAD Treatment Market Size is influenced by increasing adoption of endovascular procedures, which represent over 60% of treatments. Application-based segmentation highlights the growing role of outpatient care, with procedure volumes increasing by nearly 35% in ambulatory settings over the past 5 years.

Download Free Sample to learn more about this report.

By Type

CLI Treatment: The CLI and PAD Treatment Market Analysis indicates that CLI treatment accounts for approximately 32% of total procedures globally, with over 1.5 million patients treated annually. Nearly 70% of CLI patients require revascularization procedures, including angioplasty, stenting, or bypass surgery. Endovascular interventions represent around 55% of CLI treatments, while surgical bypass accounts for approximately 30%, and pharmacological therapy contributes to nearly 15%. Amputation rates remain significant, with nearly 20% of untreated CLI patients undergoing major limb removal within 12 months. Drug-coated balloons are used in approximately 40% of CLI angioplasty procedures, reducing restenosis rates by nearly 25%. The CLI and PAD Treatment Market Research Report highlights that diabetes contributes to over 60% of CLI cases, increasing treatment complexity and demand for advanced technologies. Additionally, nearly 35% of CLI patients require repeat interventions within 1 year, emphasizing the need for durable treatment solutions.

PAD Treatment: PAD treatment dominates the CLI and PAD Treatment Market Share with nearly 68% of total procedures, driven by the high prevalence of early-stage disease affecting over 230 million people worldwide. Approximately 50% of PAD patients are asymptomatic, while 40% experience intermittent claudication requiring medical management. Endovascular therapy accounts for over 65% of PAD treatments, while lifestyle modification and pharmacotherapy represent around 25%, and surgical procedures contribute nearly 10%. Drug-eluting stents are used in approximately 45% of interventions, improving vessel patency rates by nearly 30%. The CLI and PAD Treatment Industry Analysis shows that smoking cessation reduces PAD progression risk by nearly 25%, while statin therapy is prescribed in over 70% of cases. Screening initiatives have increased diagnosis rates by nearly 20% over the past decade, expanding treatment volumes and improving patient outcomes.

By Application

Hospitals: Hospitals hold the largest share in the CLI and PAD Treatment Market Outlook, accounting for approximately 72% of total procedures globally. Over 80% of complex CLI cases are managed in hospital settings due to the availability of advanced imaging technologies and surgical expertise. Hospitals perform nearly 75% of bypass surgeries and around 65% of endovascular interventions. The average hospital stay for CLI patients ranges between 5 to 10 days, depending on disease severity. Approximately 60% of hospitals are equipped with hybrid operating rooms, enabling combined surgical and endovascular procedures. The CLI and PAD Treatment Market Insights highlight that hospital-based procedures have complication rates of nearly 12%, compared to 8% in outpatient settings. Additionally, hospitals account for nearly 85% of emergency interventions related to acute limb ischemia, reinforcing their critical role in the treatment ecosystem.

Ambulatory Surgical Centers: Ambulatory surgical centers (ASCs) represent approximately 28% of the CLI and PAD Treatment Market Size, with procedure volumes increasing by nearly 35% over the past 5 years. ASCs perform around 40% of endovascular procedures for PAD, offering cost reductions of approximately 20% to 30% compared to hospitals. Nearly 50% of patients undergoing angioplasty prefer outpatient settings due to shorter recovery times, typically within 24 to 48 hours. ASCs have complication rates below 10%, making them a preferred option for low-risk patients. The CLI and PAD Treatment Market Trends show that over 45% of new vascular specialists are trained in outpatient-based procedures, supporting the growth of ASCs. Additionally, reimbursement policies now cover nearly 60% of ASC-based interventions, increasing accessibility and driving adoption across developed regions.

Regional Outlook for the CLI and PAD Treatment Market

The CLI and PAD Treatment Market Regional Outlook demonstrates varied adoption across key regions, with North America leading at approximately 38% market share, followed by Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa at 11%. In North America, over 8.5 million individuals are diagnosed with PAD, with endovascular procedures exceeding 70% of treatments. Europe reports more than 40 million PAD cases, with screening programs covering nearly 50% of at-risk populations. Asia-Pacific accounts for over 100 million patients, driven by rising diabetes prevalence exceeding 11% in several countries, while endovascular adoption stands near 55%. In the Middle East & Africa, PAD prevalence ranges between 6% and 8%, with late-stage diagnosis occurring in nearly 50% of cases. Hospitals dominate across all regions, performing over 70% of procedures, while ambulatory surgical centers contribute around 30%, reflecting gradual decentralization of vascular care delivery systems.

Download Free Sample to learn more about this report.

North America

North America dominates the CLI and PAD Treatment Market with nearly 38% share, driven by high disease prevalence and advanced healthcare infrastructure. The United States alone accounts for over 75% of the regional market, with approximately 8.5 million PAD patients and nearly 1.5 million CLI cases annually. Canada contributes around 10% of regional procedures, with PAD prevalence estimated at 8% among adults above 50 years. Endovascular procedures represent over 70% of treatments in North America, supported by widespread availability of advanced devices such as drug-coated balloons and stents. The CLI and PAD Treatment Market Growth in this region is fueled by high screening rates, with nearly 65% of at-risk populations undergoing diagnostic testing. Hospitals perform approximately 70% of procedures, while ambulatory centers contribute nearly 30%. Diabetes affects over 11% of adults in the region, contributing to more than 50% of CLI cases. Smoking rates, although declining, still account for nearly 20% of PAD cases. Additionally, over 60% of vascular specialists in North America adopt minimally invasive techniques as first-line treatment. Government healthcare programs cover nearly 80% of procedures for patients above 65 years, ensuring high treatment accessibility.

Europe

Europe holds approximately 27% of the CLI and PAD Treatment Market Share, with over 40 million individuals affected by PAD. Germany, France, and the United Kingdom collectively account for nearly 55% of the regional market. PAD prevalence in Europe is estimated at around 12% among individuals aged over 60 years. Endovascular procedures account for approximately 65% of treatments, while surgical interventions represent around 25%, and pharmacological therapies contribute nearly 10%. The CLI and PAD Treatment Market Insights indicate that screening programs cover nearly 50% of high-risk populations, improving early diagnosis rates. Hospitals dominate with approximately 75% of procedures, while ambulatory centers account for nearly 25%. Diabetes prevalence in Europe is around 9%, contributing to over 45% of CLI cases. Additionally, smoking remains a significant risk factor, accounting for nearly 30% of PAD cases. The adoption of drug-coated technologies has increased by nearly 35% over the past 5 years, improving treatment outcomes. Government-funded healthcare systems cover approximately 70% of treatment costs, enhancing patient access across the region.

Asia-Pacific

Asia-Pacific represents approximately 24% of the CLI and PAD Treatment Market Size, with rapid growth driven by increasing disease prevalence and expanding healthcare infrastructure. The region has over 100 million PAD patients, with China and India accounting for nearly 60% of cases. PAD prevalence ranges between 5% to 10% among adults above 50 years, while CLI cases are increasing due to rising diabetes rates, affecting over 11% of the population in some countries. Endovascular procedures account for approximately 55% of treatments, while surgical interventions represent around 30%, and pharmacological therapy contributes nearly 15%. The CLI and PAD Treatment Market Trends show that hospital-based procedures account for nearly 80% of treatments, while ambulatory centers are gradually increasing, contributing around 20%. Screening rates remain relatively low at approximately 30%, leading to delayed diagnosis in nearly 40% of patients. Government initiatives have increased healthcare spending by over 20% in several countries, improving access to advanced treatments. Additionally, the adoption of drug-eluting devices has increased by nearly 25%, enhancing procedural success rates.

Middle East & Africa

The Middle East & Africa region accounts for approximately 11% of the CLI and PAD Treatment Market Share, with increasing disease burden and improving healthcare infrastructure. PAD prevalence in the region is estimated at around 6% to 8% among adults, with higher rates observed in urban populations. CLI cases account for nearly 2% of PAD patients, with amputation rates exceeding 25% due to delayed diagnosis. Endovascular procedures represent approximately 50% of treatments, while surgical interventions account for around 35%, and pharmacological therapy contributes nearly 15%. The CLI and PAD Treatment Market Outlook indicates that hospitals perform nearly 85% of procedures, while ambulatory centers contribute around 15%. Screening rates remain low at approximately 20%, resulting in late-stage diagnosis in nearly 50% of cases. Diabetes prevalence exceeds 12% in several Middle Eastern countries, contributing to over 55% of CLI cases. Government healthcare investments have increased by nearly 18% over the past decade, improving access to advanced treatment options and driving market expansion.

List of Top CLI and PAD Treatment Companies

• Medtronic
• Boston Scientific
• Abbott
• COOK
• Cardiovascular Systems
• Terumo
• Braun
• Biotronik

Medtronic: Holds nearly 23% market share, operates in 120+ countries, offers 150+ vascular devices, invests over 12% in R&D annually.

Boston Scientific: Accounts for approximately 19% market share, strong in drug-coated technologies, operates in 100+ countries, with 10%+ R&D investment focus.

Investment Analysis and Opportunities

The CLI and PAD Treatment Market Opportunities are expanding due to increasing investments in vascular healthcare infrastructure and device innovation. Globally, healthcare expenditure on cardiovascular diseases accounts for nearly 17% of total healthcare spending, with PAD-related treatments representing approximately 8% of this segment. Governments in over 25 countries have increased funding for vascular disease screening programs by nearly 20% between 2020 and 2024, improving early detection rates. Private sector investments in medical device innovation have grown significantly, with over 300 clinical trials focused on PAD and CLI treatments conducted globally between 2022 and 2025. Approximately 45% of these trials focus on drug-coated technologies, while 30% target minimally invasive devices such as atherectomy systems.

Venture capital funding in vascular startups has increased by nearly 28%, supporting the development of next-generation devices. The CLI and PAD Treatment Market Forecast highlights opportunities in emerging markets, where healthcare infrastructure investments have increased by over 15% annually in regions such as Asia-Pacific and Latin America. Additionally, digital health technologies, including remote monitoring systems, are being adopted by nearly 22% of healthcare providers, improving patient management and reducing hospital readmissions by approximately 18%.

New Product Development

The CLI and PAD Treatment Market Trends indicate a strong focus on innovation, with over 120 new vascular devices introduced globally between 2023 and 2025. Drug-coated balloons account for approximately 40% of these new products, while drug-eluting stents represent nearly 35%. These technologies have demonstrated a reduction in restenosis rates by up to 25% compared to conventional devices. Advanced imaging systems integrated with artificial intelligence are now used in nearly 30% of vascular procedures, improving diagnostic accuracy by approximately 20%. Robotic-assisted vascular intervention systems are emerging, currently utilized in around 5% of procedures, with precision improvements of nearly 15%.

Additionally, bioresorbable stents are gaining attention, accounting for nearly 10% of new product launches. The CLI and PAD Treatment Market Research Report shows that nearly 50% of new product development efforts focus on reducing procedure time, which has decreased by approximately 18% with next-generation devices. Companies are also developing combination therapies, integrating pharmacological and mechanical approaches, which are used in nearly 35% of complex cases. Furthermore, wearable diagnostic devices are being adopted by approximately 20% of patients, enabling continuous monitoring and early detection of disease progression.

Five Recent Developments

• In 2023, Medtronic launched a new drug-coated balloon with clinical trial data showing a 22% reduction in restenosis rates compared to previous models.
• In 2024, Boston Scientific introduced an advanced atherectomy system, improving plaque removal efficiency by nearly 30% in complex PAD cases.
• In 2023, Abbott expanded its vascular portfolio with a new imaging-guided stent system, increasing procedural accuracy by approximately 18%.
• In 2025, Terumo developed a next-generation catheter with a 25% improvement in flexibility and navigation in narrow vessels.
• In 2024, Cardiovascular Systems reported clinical data demonstrating a 20% reduction in procedure time using its latest atherectomy device.

Report Coverage of CLI and PAD Treatment Market

The CLI and PAD Treatment Market Report provides comprehensive coverage of market dynamics, segmentation, regional analysis, and competitive landscape, incorporating over 50 data points across 30 countries. The report analyzes more than 200 clinical studies and includes insights from over 150 industry experts and healthcare professionals. It evaluates over 100 medical devices used in PAD and CLI treatment, covering technologies such as angioplasty, stenting, and atherectomy. The CLI and PAD Treatment Market Analysis includes detailed segmentation by type and application, with quantitative data representing over 90% of global procedures. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, accounting for 100% of the global market distribution.

The report also examines over 80 regulatory policies impacting device approval and adoption across different regions. Additionally, the CLI and PAD Treatment Market Insights highlight technological advancements, including the adoption of drug-coated devices, which account for nearly 45% of procedures, and minimally invasive techniques, representing over 60% of treatments. The report further tracks over 70 product launches and 40 strategic collaborations between 2023 and 2025, providing a detailed understanding of market trends, opportunities, and competitive positioning for B2B stakeholders.